Evidence map›Paper›PMID 32095195›Full record

ArticleCardiology research2020

Effect of Ivabradine on Left Ventricular Diastolic Function, Exercise Tolerance and Quality of Life in Patients With Heart Failure: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.

Theresa Ruba Koroma, Sallieu Kabay Samura, Yuguo Cheng, Mengxiong Tang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Exercise intensity and cardiac metabolic adaptations in elderly heart failure rehabilitation: A review.International journal of cardiology. Cardiovascular risk and prevention · 2025
    Review
  5. Review
  6. Observational
  7. Article
  8. Real-World Effectiveness of Ivabradine in Chinese Patients with Chronic Heart Failure: Interim Analysis of the POSITIVE Study.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022
    Observational
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Theresa Ruba KoromaDepartment of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China.
Sallieu Kabay SamuraSchool of Mathematical Sciences, Anhui University, Hefei, China.
Yuguo ChengDepartment of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China.
Mengxiong TangDepartment of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China.
Qilu Hospital of Shandong University · CNAnhui University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIvabradine is a heart rate-lowering drug that selectively inhibits the funny (I

methodsWe searched PubMed, EMBASE and Cochrane Central Register of Clinical Trials for studies on the effect of ivabradine on left ventricular (LV) diastolic dysfunction, exercise tolerance, QOL, readmission for worsening HF and mortality in both patients with HF with preserved ejection fraction (HFpEF) and HFrEF.

resultsThirteen RCTs with 881 patients met the inclusion criteria. According to the pooled analysis, for the HFpEF subgroup, treatment with ivabradine resulted in a decrease in early diastolic mitral inflow to late diastolic flow ratio (E/A) (standardized mean difference (SMD): -0.53; 95% confidence interval (CI): -0.99, -0.07; P < 0.000) and increase in peak oxygen uptake during exercise (VO

conclusionsIvabradine therapy is associated with improved LV diastolic function, increases exercise tolerance and hence QOL, but it has no significant effect on readmission for worsening HF and all-cause mortality.

Indexed as

Diastolic dysfunctionExercise intoleranceHeart failure with preserved ejection fractionHeart failure with reduced ejection fractionIvabradineQuality of life

Identifiers

PMID32095195
PMCPMC7011928
OpenAlexW3003914874

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.